Clinical Trial Update: Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immune response to a meningococcal ACWY conjugate vaccine in children aged 40 and 60 months; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-09-19